AP NEWS
ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against ...

June 4, 2021 GMT

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Frequency, Inc. (“Frequency” or “WPG”) (NASDAQ: FREQ) in the United States District Court for the District of Massachusetts on behalf of those who purchased or otherwise acquired Frequency publicly traded securities between November 16, 2020, and March 22, 2021, inclusive (the “Class Period”).

Frequency is a pharmaceutical company focused on the development and commercialization of a hearing loss treatment titled “FX-322,” which the Company has long promoted as a potential treatment for patients with severe sensorineural hearing loss (“SNHL”). The Complaint alleges that Frequency and CEO Lucchino misled investors about the Phase 2a study of FX-322.

Investors who purchased or otherwise acquired shares of Frequency during the Class Period should contact the Firm prior to the August 2, 2021 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.

Please visit our website at http://www.gme-law.com for more information about the firm.